المؤلفون: Do TTH, Bui QTT, Ha BTT, Le TM, Le VT, Nguyen QCT, Lakin KJ, Dang TT, Bui LV, Le TC, Tran ATH, Pham HTT, Nguyen TV

المصدر: International Journal of Women's Health, Vol Volume 15, Pp 599-609 (2023)

مصطلحات موضوعية: srq-20, screening, common mental disorders, pregnant women, vietnam., Gynecology and obstetrics, RG1-991

وصف الملف: electronic resource

Relation: https://www.dovepress.com/using-the-who-self-reporting-questionnaire-20-srq-20-to-detect-symptom-peer-reviewed-fulltext-article-IJWH; https://doaj.org/toc/1179-1411

URL الوصول: https://doaj.org/article/3995e3b736bf483a8f1c542eb5ab483a

المؤلفون: Nguyen KD; Faculty of Environment, Van Lang University, Ho Chi Minh City 70000, Vietnam., Thu TT; Faculty of Environment, Van Lang University, Ho Chi Minh City 70000, Vietnam., Tran ATH; Faculty of Environment, Van Lang University, Ho Chi Minh City 70000, Vietnam., Le OTK; Faculty of Environment, Van Lang University, Ho Chi Minh City 70000, Vietnam., Sagadevan S; Nanotechnology and Catalysis Research Centre, Universiti Malaya, Kuala Lumpur 50603, Malaysia., Mohd Kaus NH; School of Chemical Sciences, Universiti Sains Malaysia, Penang 11800, Malaysia.

المصدر: ACS omega [ACS Omega] 2023 Oct 24; Vol. 8 (44), pp. 41258-41272. Date of Electronic Publication: 2023 Oct 24 (Print Publication: 2023).

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Chemical Society Country of Publication: United States NLM ID: 101691658 Publication Model: eCollection Cited Medium: Internet ISSN: 2470-1343 (Electronic) Linking ISSN: 24701343 NLM ISO Abbreviation: ACS Omega Subsets: PubMed not MEDLINE

المؤلفون: Thomas A; Laboratory of Experimental Urology, Department of Development and Regeneration, KU Leuven, Leuven, Belgium.; Department of Urology, University Hospitals Leuven, Leuven, Belgium.; Department of Urology and Pediatric Urology, University Medical Center Mainz, Mainz, Germany., Necchi A; Genitourinary Medical Oncology, IRCCS San Raffaele Hospital and Scientific Institute, Milan, Italy., Muneer A; Department of Urology, University College London Hospitals, London, UK.; National Institute for Health Research (NIHR) Biomedical Research Centre, University College London Hospitals, London, UK.; Division of Surgery and Interventional Science, University College London, London, UK., Tobias-Machado M; Section of Urologic Oncology, Department of Urology, ABC Medical School, Instituto do Cancer Vieira de Carvalho, São Paulo, Brazil., Tran ATH; Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK., Van Rompuy AS; Department of Pathology, University Hospitals Leuven, Leuven, Belgium., Spiess PE; Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL, USA., Albersen M; Laboratory of Experimental Urology, Department of Development and Regeneration, KU Leuven, Leuven, Belgium. maarten.albersen@uzleuven.be.; Department of Urology, University Hospitals Leuven, Leuven, Belgium. maarten.albersen@uzleuven.be.

المصدر: Nature reviews. Disease primers [Nat Rev Dis Primers] 2021 Feb 11; Vol. 7 (1), pp. 11. Date of Electronic Publication: 2021 Feb 11.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101672103 Publication Model: Electronic Cited Medium: Internet ISSN: 2056-676X (Electronic) Linking ISSN: 2056676X NLM ISO Abbreviation: Nat Rev Dis Primers Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Squamous Cell*/diagnosis , Carcinoma, Squamous Cell*/epidemiology , Carcinoma, Squamous Cell*/therapy , Penile Neoplasms*/diagnosis , Penile Neoplasms*/epidemiology , Penile Neoplasms*/etiology, Humans ; Lymph Nodes ; Male ; Papillomaviridae ; Quality of Life

المؤلفون: Woods BS; Centre for Health Economics, University of York, York, UK. Electronic address: beth.woods@york.ac.uk., Sideris E; Centre for Health Economics, University of York, York, UK., Sydes MR; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK., Gannon MR; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK., Parmar MKB; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK., Alzouebi M; Weston Park Hospital, Sheffield, UK., Attard G; The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK., Birtle AJ; Rosemere Cancer Centre, Royal Preston Hospital, Preston, UK., Brock S; Dorset Cancer Centre, Poole Hospital NHS Foundation Trust, Poole, UK., Cathomas R; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland; Kantonsspital Graubünden, Chur, Switzerland., Chakraborti PR; Royal Derby Hospital, Derby, UK., Cook A; Gloucestershire Oncology Centre, Cheltenham, UK., Cross WR; Department of Urology, Leeds Teaching Hospitals NHS Trust, Leeds, UK., Dearnaley DP; The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK., Gale J; Portsmouth Oncology Centre, Queen Alexandra Hospital, Portsmouth, UK., Gibbs S; Barking, Havering and Redbridge University Hospitals NHS Trust, Romford, UK., Graham JD; Beacon Centre, Musgrove Park Hospital, Taunton, UK., Hughes R; Mount Vernon Group, Mount Vernon Hospital, Northwood, UK., Jones RJ; University of Glasgow, UK., Laing R; St Luke's Cancer Centre, Royal Surrey NHS Trust, Guildford, UK., Mason MD; School of Medicine, Cardiff University, Cardiff, UK., Matheson D; University of Wolverhampton, Wolverhampton, UK., McLaren DB; Department of Oncology, Western General Hospital, Edinburgh, UK., Millman R; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK., O'Sullivan JM; Centre for Cancer Research and Cell Biology, Queen's University, Belfast, UK., Parikh O; Department of Oncology, East Lancashire Hospitals NHS Trust, Burnley, UK., Parker CC; The Royal Marsden NHS Foundation Trust, London, UK., Peedell C; South Tees NHS Foundation Trust, Middlesbrough, UK., Protheroe A; Department of Oncology, Churchill Hospital, Oxford, UK., Ritchie AWS; Gloucestershire Royal Hospital Foundation Trust, Gloucester, UK., Robinson A; Sussex Cancer Centre, Royal Sussex County Hospital, Brighton, UK., Russell JM; Institute of Cancer Sciences, University of Glasgow, Glasgow, UK; Forth Valley Royal Hospital, Larbert, UK., Simms MS; Hull and East Yorkshire Hospitals NHS Trust, Hull, UK., Srihari NN; Shrewsbury and Telford Hospitals NHS Trust, Shrewsbury, UK., Srinivasan R; Royal Devon & Exeter NHS Foundation Trust, Exeter, UK., Staffurth JN; Velindre Cancer Centre, Cardiff and School of Medicine, Cardiff University, Cardiff, UK., Sundar S; University of Nottingham, Nottingham, UK., Thalmann GN; Department of Urology, University Hospital Bern, Bern, Switzerland., Tolan S; Clatterbridge Cancer Centre, Birkenhead, UK., Tran ATH; The Christie NHS Foundation Trust, Manchester, UK., Tsang D; Southend and Basildon Hospitals, Southend, UK., Wagstaff J; Swansea University College of Medicine, Swansea, UK., James ND; Queen Elizabeth Hospital, Edgbaston, Birmingham, UK., Sculpher MJ; Centre for Health Economics, University of York, York, UK.

المصدر: European urology oncology [Eur Urol Oncol] 2018 Dec; Vol. 1 (6), pp. 449-458. Date of Electronic Publication: 2018 Sep 14.

نوع المنشور: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101724904 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2588-9311 (Electronic) Linking ISSN: 25889311 NLM ISO Abbreviation: Eur Urol Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Cost-Benefit Analysis*, Antineoplastic Combined Chemotherapy Protocols/*economics , Prostatic Neoplasms/*drug therapy , Prostatic Neoplasms/*mortality, Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Docetaxel/administration & dosage ; Docetaxel/economics ; Humans ; Male ; Middle Aged ; Neoplasm Recurrence, Local/drug therapy ; Prognosis ; Prostatic Neoplasms/economics ; Prostatic Neoplasms/pathology ; Quality-Adjusted Life Years ; Standard of Care ; United Kingdom

المؤلفون: Parker CC; Academic Urology Unit, Royal Marsden Hospital, London, UK; Institute of Cancer Research, London, UK. Electronic address: chris.parker@icr.ac.uk., James ND; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK., Brawley CD; Medical Research Council (MRC) Clinical Trials Unit at University College London (UCL), London, UK., Clarke NW; Genito-Urinary Cancer Research Group, Department of Surgery, The Christie Hospital, Manchester, UK; Department of Urology, Salford Royal Hospitals, Manchester, UK., Hoyle AP; Genito-Urinary Cancer Research Group, Department of Surgery, The Christie Hospital, Manchester, UK; Department of Urology, Salford Royal Hospitals, Manchester, UK., Ali A; Genito-Urinary Cancer Research Group, Department of Surgery, The Christie Hospital, Manchester, UK; The FASTMAN/Genito-Urinary Cancer Research Groups, Division of Cancer Sciences, and Belfast-Manchester Movember Centre of Excellence, Manchester Cancer Research Centre, University of Manchester, Manchester, UK., Ritchie AWS; Medical Research Council (MRC) Clinical Trials Unit at University College London (UCL), London, UK., Attard G; UCL Cancer Institute, UCL, London, UK., Chowdhury S; Department of Medical Oncology, Guy's & St Thomas' NHS Foundation Trust, London, UK., Cross W; Department of Urology, St James University Hospital, Leeds, UK., Dearnaley DP; Academic Urology Unit, Royal Marsden Hospital, London, UK; Institute of Cancer Research, London, UK., Gillessen S; Division of Cancer Sciences, University of Manchester and the Christie, Manchester, UK; Division of Oncology and Haematology, Kantonsspital, St Gallen, Switzerland., Gilson C; Medical Research Council (MRC) Clinical Trials Unit at University College London (UCL), London, UK., Jones RJ; Beatson West of Scotland Cancer Centre, University of Glasgow, Glasgow, UK., Langley RE; Medical Research Council (MRC) Clinical Trials Unit at University College London (UCL), London, UK., Malik ZI; The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, UK., Mason MD; Division of Cancer & Genetics, School of Medicine, Cardiff University, Cardiff, UK., Matheson D; Faculty of Education, Health and Wellbeing, University of Wolverhampton, Wolverhampton, UK., Millman R; Medical Research Council (MRC) Clinical Trials Unit at University College London (UCL), London, UK., Russell JM; Institute of Cancer Sciences, University of Glasgow, Glasgow, UK., Thalmann GN; Department of Urology, University Hospital, Inselspital, Bern, Switzerland., Amos CL; Medical Research Council (MRC) Clinical Trials Unit at University College London (UCL), London, UK., Alonzi R; Mount Vernon Cancer Centre, London, UK., Bahl A; Bristol Haematology and Oncology Centre, Bristol, UK., Birtle A; Rosemere Cancer Centre, Lancashire Teaching Hospitals, Preston, UK; School of Cancer Sciences, University of Manchester, Manchester, UK., Din O; Department of Clinical Oncology, Weston Park Cancer Centre, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK., Douis H; Department of Radiology, University Hospital Birmingham NHS Foundation Trust, Birmingham, UK., Eswar C; The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, UK., Gale J; Portsmouth Oncology Centre, Queen Alexandra Hospital, Portsmouth, UK., Gannon MR; Department of Health Services Research, London School of Hygiene & Tropical Medicine, London, UK., Jonnada S; Department of Oncology, Gloucestershire Hospitals NHS Foundation Trust, Gloucester, UK., Khaksar S; St Luke's Cancer Centre, Royal Surrey County Hospital, Guildford, UK., Lester JF; Velindre Cancer Centre, Cardiff, UK., O'Sullivan JM; Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, UK., Parikh OA; Department of Clinical Oncology, East Lancashire Hospitals NHS Trust, Blackburn, UK., Pedley ID; Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne, UK., Pudney DM; Clinical Oncology, Singleton Hospital, Swansea, UK., Sheehan DJ; Exeter Oncology Centre, Royal Devon & Exeter Hospital, Exeter, UK., Srihari NN; Department of Oncology, Shrewsbury and Telford Hospitals NHS Trust, Shrewsbury, UK., Tran ATH; Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK., Parmar MKB; Medical Research Council (MRC) Clinical Trials Unit at University College London (UCL), London, UK., Sydes MR; Medical Research Council (MRC) Clinical Trials Unit at University College London (UCL), London, UK. Electronic address: mrcctu.stampede-publications@ucl.ac.uk.

مؤلفون مشاركون: Systemic Therapy for Advanced or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators

المصدر: Lancet (London, England) [Lancet] 2018 Dec 01; Vol. 392 (10162), pp. 2353-2366. Date of Electronic Publication: 2018 Oct 21.

نوع المنشور: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE

مواضيع طبية MeSH: Prostatic Neoplasms/*pathology , Prostatic Neoplasms/*radiotherapy, Aged ; Antineoplastic Agents/therapeutic use ; Disease-Free Survival ; Docetaxel/therapeutic use ; Gonadotropin-Releasing Hormone/agonists ; Gonadotropin-Releasing Hormone/antagonists & inhibitors ; Humans ; Lymph Nodes/pathology ; Male ; Middle Aged ; Neoplasm Metastasis ; Orchiectomy ; Prostatic Neoplasms/drug therapy ; Prostatic Neoplasms/surgery ; Radiotherapy/adverse effects ; Standard of Care ; Survival Analysis ; Treatment Outcome